A focus on 3D culture systems, CRISPR engineering, 3D bioprinting and organ-on-a-chip technologies
SMI GROUP REPORTS: Next annual 3D Cell Culture meeting to showcase advancements in the next generation of 3D bioprinting and organ-on-a-chip technologies.
SMi’s 2nd annual conference on 3D Cell Culture will return next February to Central London and will feature a notable speaker line-up from the likes of GSK, AstraZeneca, Roche and Novartis Institutes for Biomedical Research and more. The agenda for 2018 will focus on 3 key areas including technological advancements; regenerative medicine and drug screening; and 3D bioprinting and organ-on-a-chip technologies.
1. Technical Advancements to Enhance 3D Culture Systems
Attendees will explore a rapidly developing series of technologies enabling the evolution of complex models of human tissues and in vitro assays with the University of Durham. The session will also include updates into electrospun micro-scaffold based biology with Aurelia Bioscience; 3D application of the next generation jellyfish collagen biomaterials with Jellagen Pty Ltd; and the potential of advanced cell culture models for the understanding of disease and compound testing with Immunocore.
2. A Two-Part Focus on Regenerative Medicine and Drug Screening
Can 3D cell culture improve the prediction of hepatotoxicity in early phase screening?
Why is there a strong need for complex in vitro models for drug safety assessment?
How effective are CRISPR engineered organoids for modelling and screening genetic & infectious brain diseases?
What are the latest technologies on 3D-culture strategies for generation of stem cell-derived beta cells?
What are the key challenges for regenerative medicine?
These are just some of the questions addressed in the two-part focus on regenerative medicine and drug screening with keynotes from GSK, Novartis, Nexcelom, Roche, University College London, Kugelmeiers and AstraZeneca.
3. 3D Bioprinting and Organ-on-a-Chip Technologies
The agenda will explore the synonymy of 3D bioprinting and 3D cell culturing in line with cancer research through an address by Herlot-Watt University. Highlights will also include insight into the scientific concept, design principles and fabrication of OOC with TissUse; and a case study in optimising in vitro prevascularized tumour models through co-cultured spheroids with AstraZeneca.
3D Cell Culture 2018 is sponsored by Jellagen Pty Ltd and Nexcelom Bioscience. It will take place on 21st and 22nd February at the Holiday Inn Kensington Forum in Central London, UK.
For those looking to attend, there is currently a £400 early bird saving online which expires on 31st October
Further information including a full speaker line-up and detailed agenda is available online at here.